aap Implantate Valuation
Is AAQ1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AAQ1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AAQ1's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AAQ1's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AAQ1?
Key metric: As AAQ1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is AAQ1's PS Ratio? | |
|---|---|
| PS Ratio | 1.8x |
| Sales | €11.96m |
| Market Cap | €21.96m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | -8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does AAQ1's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.7x | ||
NN6 NanoRepro | 5.5x | n/a | €19.6m |
GME Geratherm Medical | 0.8x | 1.9% | €15.1m |
AUG Audientes | 12.6x | n/a | €6.9m |
PUS PULSION Medical Systems | 3.8x | n/a | €134.4m |
AAQ1 aap Implantate | 1.8x | n/a | €22.0m |
Price-To-Sales vs Peers: AAQ1 is good value based on its Price-To-Sales Ratio (1.8x) compared to the peer average (3.4x).
Price to Sales Ratio vs Industry
How does AAQ1's PS Ratio compare vs other companies in the DE Medical Equipment Industry?
Price-To-Sales vs Industry: AAQ1 is good value based on its Price-To-Sales Ratio (1.8x) compared to the European Medical Equipment industry average (3.4x).
Price to Sales Ratio vs Fair Ratio
What is AAQ1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.8x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate AAQ1's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Sensus Healthcare
US$125.2m
A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.
5TX
US$7.25
7D
16.0%
1Y
272.6%
Ship Healthcare Holdings
JP¥196.5b
Engages in the medical, healthcare, welfare, and nursing care businesses worldwide.
5EZ
JP¥12.40
7D
-3.1%
1Y
-4.6%
Shandong Weigao Group Medical Polymer
HK$20.8b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.57
7D
0%
1Y
-36.0%